{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:45:37Z","timestamp":1790660737572,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Vladimir"},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Partners in Health"},{"name":"SORT IT"},{"name":"LHL International"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rates of drug-resistant tuberculosis (DR-TB) are increasing worldwide. Tuberculosis preventive treatment (TPT) for contacts of people with active TB is essential to halt infection progression and transmission. While newer TPT regimens for exposure to drug-susceptible and rifampin (R)-resistant strains (MDR-TB\/RR-TB) are expanding, optimal treatment for contacts exposed to fluoroquinolone-resistant strains of TB (pre-XDR- or XDR-TB) remains unclear. In 2019\u20132020, Vladimir City, Russia, introduced moxifloxacin (Mfx)- and bedaquiline (Bdq)-based TPT regimens to prevent disease development in contacts exposed to MDR\/RR-TB and pre-XDR-TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of adult TB contacts, people experiencing homelessness, and people with HIV who received TPT in Vladimir between 2019 and 2020. Those without TB disease but with indications for TPT were offered 1 of 6 regimens, based on drug-susceptibility testing results of the index patient: rifapentine\/isoniazid (3HP), isoniazid (6H), rifabutin\/isoniazid (3HRb), 4R, 4Mfx, or 3Bdq. Adverse drug reactions (ADRs) were monitored with monthly lab tests and electrocardiogram (ECGs). Outcome measures included ADRs, TPT completion, and TB disease incidence during the 12-month follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over 24 months, 403 people started TPT. No life-threatening ADRs or deaths occurred. The lowest ADR rate and highest completion were seen with 3Bdq (95.2%) compared to 3HP (75.9%, Mid-P exact = .03). Tuberculosis incidence per 1000 person-years was 4 times higher among eligible individuals who declined TPT versus those initiating it.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Preventive therapy for drug-resistant TB, including fluoroquinolone-resistant strains, is acceptable, safe, and effective. Implementation of comprehensive TPT programs in high-burden DR-TB settings can protect contacts and reduce transmission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf701","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:00:36Z","timestamp":1769086836000},"page":"25-34","source":"Crossref","is-referenced-by-count":3,"title":["Implementing a Program of Comprehensive Tuberculosis Preventive Treatment: Safety, Effectiveness, and Acceptability of Moxifloxacin or Bedaquiline Use for Contacts Exposed to Drug-Resistant Strains"],"prefix":"10.1093","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9732-7224","authenticated-orcid":false,"given":"Alexandra V","family":"Solovyeva","sequence":"first","affiliation":[{"name":"Independent Nonprofit Organization Center of Partnership Assistance in Healthcare \u201cZdorovye.ru\u201d , Moscow ,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3416-6477","authenticated-orcid":false,"given":"Grigory V","family":"Volchenkov","sequence":"additional","affiliation":[{"name":"Vladimir Regional TB Control Center , Vladimir ,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana I","family":"Ponomarenko","sequence":"additional","affiliation":[{"name":"Independent Nonprofit Organization Center of Partnership Assistance in Healthcare \u201cZdorovye.ru\u201d , Moscow ,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana A","family":"Kuznezova","sequence":"additional","affiliation":[{"name":"Vladimir Regional TB Control Center , Vladimir ,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana R","family":"Somova","sequence":"additional","affiliation":[{"name":"Vladimir Regional TB Control Center , Vladimir ,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia V","family":"Belova","sequence":"additional","affiliation":[{"name":"Vladimir Regional TB Control Center , Vladimir ,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2725-0248","authenticated-orcid":false,"given":"Sven Gudmund","family":"Hinderaker","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-792X","authenticated-orcid":false,"given":"Einar","family":"Heldal","sequence":"additional","affiliation":[{"name":"LHL International , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6967-3305","authenticated-orcid":false,"given":"Salmaan","family":"Keshavjee","sequence":"additional","affiliation":[{"name":"Department of Global Health and Social Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Partners In Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"2026072309012131700_ciaf701-B1","volume-title":"Implementing the End TB strategy: the essentials. 2022 update","author":"World Health Organization","year":"2022"},{"key":"2026072309012131700_ciaf701-B2","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"key":"2026072309012131700_ciaf701-B3","author":"World Health Organization","year":"2020"},{"key":"2026072309012131700_ciaf701-B4","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026072309012131700_ciaf701-B5","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S0140-6736(15)00320-7","article-title":"Stopping the body count: a comprehensive approach to move towards zero tuberculosis deaths","volume":"386","author":"Keshavjee","year":"2015","journal-title":"Lancet"},{"key":"2026072309012131700_ciaf701-B6","author":"World Health Organization","year":"2025"},{"key":"2026072309012131700_ciaf701-B7","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cit643","article-title":"Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis","volume":"58","author":"Shah","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026072309012131700_ciaf701-B8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/cid\/cix208","article-title":"Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis","volume":"64","author":"Marks","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026072309012131700_ciaf701-B9","first-page":"EVIDoa2400190","article-title":"A meta-analysis of levofloxacin for contacts of multidrug-resistant tuberculosis","volume":"4","author":"Duong","year":"2024","journal-title":"NEJM Evidence"},{"key":"2026072309012131700_ciaf701-B10","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa2314325","article-title":"Levofloxacin for the prevention of multidrug-resistant tuberculosis in Vietnam","volume":"391","author":"Fox","year":"2024","journal-title":"N Engl J Med"},{"key":"2026072309012131700_ciaf701-B11","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2314318","article-title":"Levofloxacin preventive treatment in children exposed to MDR tuberculosis","volume":"391","author":"Hesseling","year":"2024","journal-title":"N Engl J Med"},{"key":"2026072309012131700_ciaf701-B12","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/cid\/ciaa327","article-title":"Risk factors for adverse events in household contacts prescribed preventive treatment for drug-resistant tuberculosis exposure","volume":"72","author":"Malik","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026072309012131700_ciaf701-B13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5588\/ijtld.21.0443","article-title":"Fluoroquinolone preventive therapy for children exposed to MDR-TB","volume":"26","author":"Gureva","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026072309012131700_ciaf701-B14","author":"World Health Organization","year":"2024"},{"key":"2026072309012131700_ciaf701-B15","year":"2025"},{"key":"2026072309012131700_ciaf701-B16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/cid\/ciaa613","article-title":"Concordance of drug-resistance profiles between persons with drug-resistant tuberculosis and their household contacts: a systematic review and meta-analysis","volume":"73","author":"Chiang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026072309012131700_ciaf701-B17","volume-title":"Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis","author":"Bayona","year":"2003"},{"key":"2026072309012131700_ciaf701-B18","author":"World Health Organization"},{"key":"2026072309012131700_ciaf701-B19","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant Tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl JMed"},{"key":"2026072309012131700_ciaf701-B20","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1164\/rccm.201103-0397OC","article-title":"Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection","volume":"184","author":"Zhang","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026072309012131700_ciaf701-B21","volume-title":"Vladimir oblast in figures (brief statistical digest)","author":"Territorial Office of the Federal State Statistics Service for the Vladimir Oblast","year":"2023"},{"key":"2026072309012131700_ciaf701-B22"},{"key":"2026072309012131700_ciaf701-B23","first-page":"101","volume-title":"Resources and activities of tuberculosis control organizations in the Russian federation in 2017\u20132018 (statistical materials)","author":"Nechaeva","year":"2018"},{"key":"2026072309012131700_ciaf701-B24"},{"key":"2026072309012131700_ciaf701-B25"},{"key":"2026072309012131700_ciaf701-B26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1473-3099(21)00261-9","article-title":"The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-\u03b3 release assays: a systematic review and meta-analysis","volume":"22","author":"Krutikov","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026072309012131700_ciaf701-B27","author":"World Health Organization","year":"2022"},{"key":"2026072309012131700_ciaf701-B28","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"2026072309012131700_ciaf701-B29","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.200807-1152OC","article-title":"Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis","volume":"180","author":"Ibrahim","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026072309012131700_ciaf701-B30","first-page":"e28519","article-title":"Bedaquiline: a novel diarylquinoline for multidrug-resistant pulmonary tuberculosis","volume":"14","author":"Deshkar","year":"2022","journal-title":"Cureus"},{"key":"2026072309012131700_ciaf701-B31"},{"key":"2026072309012131700_ciaf701-B32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Tuberculosis trials consortium. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026072309012131700_ciaf701-B33"},{"key":"2026072309012131700_ciaf701-B34","first-page":"CD001363","article-title":"Isoniazid for preventing tuberculosis in non-HIV infected persons","volume":"1999","author":"Smieja","year":"2000","journal-title":"Cochrane Database of Syst Rev"},{"key":"2026072309012131700_ciaf701-B35","first-page":"CD000171","article-title":"Treatment of latent tuberculosis infection in HIV infected persons","volume":"2010","author":"Akolo","year":"2010","journal-title":"Cochrane Database of Syst Rev"},{"key":"2026072309012131700_ciaf701-B36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1164\/rccm.200303-390OC","article-title":"Use of isoniazid for latent tuberculosis infection in a public health clinic","volume":"168","author":"LoBue","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026072309012131700_ciaf701-B37","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1164\/ajrccm.162.5.2003028","article-title":"Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis","volume":"162","author":"Jasmer","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2026072309012131700_ciaf701-B38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/imj.12979","article-title":"Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection","volume":"46","author":"Gray","year":"2016","journal-title":"Intern Med J"},{"key":"2026072309012131700_ciaf701-B39","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.13.0028","article-title":"Treatment for LTBI in contacts of MDR-TB patients, federated states of Micronesia, 2009\u20132012","volume":"18","author":"Bamrah","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026072309012131700_ciaf701-B40","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1093\/cid\/ciz502","article-title":"Tuberculosis preventive therapy for individuals exposed to drug-resistant tuberculosis: feasibility and safety of a community-based delivery of fluoroquinolone-containing preventive regimen","volume":"70","author":"Malik","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026072309012131700_ciaf701-B41","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12879-025-10832-7","article-title":"Treatment completion and safety profile of once-weekly 3HP regimen for tuberculosis preventive treatment in children and adolescents: a systematic review","volume":"25","author":"Pangprasertkul","year":"2025","journal-title":"BMC Infect Dis"},{"key":"2026072309012131700_ciaf701-B42","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/JCMA.0000000000000605","article-title":"Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: a systematic review and meta-analysis","volume":"84","author":"Tseng","year":"2021","journal-title":"J Chin Med Assoc"},{"key":"2026072309012131700_ciaf701-B43","first-page":"520","article-title":"High tuberculosis preventive treatment uptake and completion rates using a person-centered approach among tuberculosis household contact in Yogyakarta","volume":"8","author":"Felisia","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"2026072309012131700_ciaf701-B44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ebch.1962","article-title":"Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB","volume":"9","author":"Sharma","year":"2014","journal-title":"Evid Based Child Health"},{"key":"2026072309012131700_ciaf701-B45","first-page":"e25083","article-title":"Use of isoniazid monotherapy in comparison to rifamycin-based regimen for the treatment of patients with latent tuberculosis: a systematic review","volume":"14","author":"Shahid","year":"2022","journal-title":"Cureus"},{"key":"2026072309012131700_ciaf701-B46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026072309012131700_ciaf701-B47","author":"World Health Organization","year":"2024"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf701\/66722360\/ciaf701.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/1\/25\/66722360\/ciaf701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/1\/25\/66722360\/ciaf701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:01:35Z","timestamp":1784811695000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/1\/25\/8456170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,3]]},"published-print":{"date-parts":[[2026,7,23]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf701","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,15]]},"published":{"date-parts":[[2026,2,3]]}}}